Improved Response and Survival With Cabozantinib in Patients With Advanced RCC Regardless of Age
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Outcomes Based on Age in the Phase III METEOR Trial of Cabozantinib Versus Everolimus in Patients With Advanced Renal Cell Carcinoma
Eur. J. Cancer 2020 Feb 01;126(xx)1-10, F Donskov, RJ Motzer, E Voog, E Hovey, C Grüllich, LM Nott, K Cuff, T Gil, NV Jensen, C Chevreau, S Negrier, R Depenbusch, L Bergmann, I Cornelio, A Champsaur, B Escudier, S Pal, T Powles, TK ChoueiriFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.